Tradestie Institutional Equity Comparison Engine

OVID vs CELU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OVID Overall Edge

OVID Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical, Options & Structure while CELU counters with relative strength in Growth & Margin. Fundamentally, OVID trades at 1.8x Forward P/E with -4693.7% operating margin (-88.3% YoY revenue) versus CELU at N/M Forward P/E and -254.0% operating margin (-5.3% YoY). In options structure, OVID sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OVID
OVID 1.8x vs CELU N/M Fwd P/E
Growth & Margin Winner CELU
Op Margin -4693.7% vs -254.0% ยท YoY -88.3% vs -5.3%
Momentum & Technical Winner OVID
1Y +71.9% vs -72.6% ยท 52W Pos 52% vs 2%
Options & Structure Winner OVID
BREAKDOWN (<1st %ile IV) vs BREAKDOWN (50th %ile IV)
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
1M Return -7.17%
1Y Return +71.88%
Forward P/E 1.8x
Unified AI Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
1M Return -55.9%
1Y Return -72.6%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OVID +71.88% CELU -72.6% Spread: +144.48 pp (OVID Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OVID Revenue CELU Revenue OVID Op. Margin CELU Op. Margin Margin Edge
FY2020 $10M $10M -645.4% -1064.0% OVID
FY2021 $210M $20M 59.6% -511.2% OVID
FY2022 $0M $20M -3696.4% -142.4% CELU
FY2023 $0M $20M -15122.7% -844.4% CELU
FY2024 $0M $50M -10933.7% -70.7% CELU
FY2025 $10M $30M -585.2% -230.9% CELU

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OVID (8) vs CELU (2)
Institutional Metric OVID CELU Criterion Row Winner
Market Capitalization Scale $424.6M $15.2M Larger Scale OVID
Trailing P/E Ratio Valuation 1.8x N/M Lower Multiple OVID
Forward P/E Ratio Valuation 1.8x N/M Lower Multiple OVID
Revenue Growth (YoY) Growth -88.3% -5.3% Higher Growth CELU
Operating Margin (TTM) Profitability -4693.7% -254.0% Higher Margin CELU
Net Profit Margin Profitability 0.0% -245.7% Higher Margin OVID
Return on Equity (ROE) Capital Efficiency -35.4% -6367.2% Higher ROE OVID
52-Week Range Position Momentum 52% ($1โ€“$3) 2% ($0โ€“$3) Stronger Trend OVID
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 97% Vol 2.01ฮฒ ยท 135% Vol Lower Realized Risk OVID
Unified Institutional Score Composite Signal 52.3 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite OVID

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OVID vs CELU Buy Guide
OVID BREAKDOWN
154d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OVID Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OVID nor CELU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.